FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013784259> ?p ?o ?g. }

• W2013784259 endingPage "3069" @default.
• W2013784259 startingPage "3069" @default.
• W2013784259 abstract "To evaluate the efficacy and safety of sodium hyaluronate solution (SH) in endoscopic submucosal dissection (ESD) of gastric neoplasms.A prospective multicenter randomized, double blind, controlled trial was designed and utilized in this study. A total of 76 patients with 5-20 mm sized gastric neoplasms were enrolled at three academic hospitals in South Korea from June 2011 to October 2011. Patients were randomly assigned to the 0.4% sodium hyaluronate or control groups. All lesions underwent endoscopic ESD. ESD was performed with 0.4%SH and normal saline (NS) solution for submucosal injection. Efficacy was assessed using en bloc resection and the number of additional injections. Secondary evaluation variables were the volume of injection material, steepness of mucosal elevation, bleeding rate, procedural time and operator satisfaction. Finally, the safety was assessed by analyzing adverse events during the study.The usefulness rate in the 0.4%SH group and the controlled group had statistically significant difference under intention to treat (ITT) analysis (90.91% vs 61.11% P = 0.0041). Under per protocol (PP), the usefulness rate is statistically significant different (93.10% vs 61.76%, P = 0.0036). The difference in volume of the solution injected between 0.4%SH group and the controlled group and NS group was also statistically significant under intention to treat and per protocol analysis (ITT: 0.03 ± 0.02 mL vs 0.06 ± 0.03 mL, P = 0.0003, PP: 0.03 ± 0.02 mL vs 0.06 ± 0.03 mL, P = 0.0004). Satisfaction above the grade good was significantly higher in the SH group under intention to treat and per protocol analysis (ITT: 90.91% vs 61.11%, P = 0.0041, PP = 93.11% vs 61.77%, P = 0.0022). Adverse events above grade 3 were not noticed in either group. All adverse events were treated and were judged as not associated with the submucosal injection solutions.0.4%SH solution is a safe and effective agent that doesn't cause any significant adverse events and is useful for submucosal injection during ESD." @default.
• W2013784259 created "2016-06-24" @default.
• W2013784259 creator A5006728335 @default.
• W2013784259 creator A5034545620 @default.
• W2013784259 creator A5055171803 @default.
• W2013784259 creator A5067036364 @default.
• W2013784259 creator A5075633389 @default.
• W2013784259 creator A5076247836 @default.
• W2013784259 creator A5077437724 @default.
• W2013784259 creator A5086238156 @default.
• W2013784259 creator A5089745757 @default.
• W2013784259 date "2013-01-01" @default.
• W2013784259 modified "2023-10-18" @default.
• W2013784259 title "Efficacy and safety of 0.4 percent sodium hyaluronate for endoscopic submucosal dissection of gastric neoplasms" @default.
• W2013784259 cites W1497159352 @default.
• W2013784259 cites W1966581423 @default.
• W2013784259 cites W1967332781 @default.
• W2013784259 cites W1976048296 @default.
• W2013784259 cites W1980109594 @default.
• W2013784259 cites W1981142725 @default.
• W2013784259 cites W2000315396 @default.
• W2013784259 cites W2022241406 @default.
• W2013784259 cites W2024590196 @default.
• W2013784259 cites W2031440912 @default.
• W2013784259 cites W2045123221 @default.
• W2013784259 cites W2060471239 @default.
• W2013784259 cites W2069455240 @default.
• W2013784259 cites W2089555541 @default.
• W2013784259 cites W2093712322 @default.
• W2013784259 cites W2096706944 @default.
• W2013784259 cites W2105426062 @default.
• W2013784259 cites W2106459991 @default.
• W2013784259 cites W2153215948 @default.
• W2013784259 cites W2162167772 @default.
• W2013784259 cites W2404562391 @default.
• W2013784259 cites W2408610322 @default.
• W2013784259 cites W2410866349 @default.
• W2013784259 cites W2418392580 @default.
• W2013784259 cites W2433337001 @default.
• W2013784259 cites W2795268694 @default.
• W2013784259 doi "https://doi.org/10.3748/wjg.v19.i20.3069" @default.
• W2013784259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3662946" @default.
• W2013784259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23716986" @default.
• W2013784259 hasPublicationYear "2013" @default.
• W2013784259 type Work @default.
• W2013784259 sameAs 2013784259 @default.
• W2013784259 citedByCount "15" @default.
• W2013784259 countsByYear W20137842592014 @default.
• W2013784259 countsByYear W20137842592015 @default.
• W2013784259 countsByYear W20137842592017 @default.
• W2013784259 countsByYear W20137842592018 @default.
• W2013784259 countsByYear W20137842592019 @default.
• W2013784259 countsByYear W20137842592020 @default.
• W2013784259 countsByYear W20137842592021 @default.
• W2013784259 countsByYear W20137842592022 @default.
• W2013784259 crossrefType "journal-article" @default.
• W2013784259 hasAuthorship W2013784259A5006728335 @default.
• W2013784259 hasAuthorship W2013784259A5034545620 @default.
• W2013784259 hasAuthorship W2013784259A5055171803 @default.
• W2013784259 hasAuthorship W2013784259A5067036364 @default.
• W2013784259 hasAuthorship W2013784259A5075633389 @default.
• W2013784259 hasAuthorship W2013784259A5076247836 @default.
• W2013784259 hasAuthorship W2013784259A5077437724 @default.
• W2013784259 hasAuthorship W2013784259A5086238156 @default.
• W2013784259 hasAuthorship W2013784259A5089745757 @default.
• W2013784259 hasBestOaLocation W20137842591 @default.
• W2013784259 hasConcept C126322002 @default.
• W2013784259 hasConcept C141071460 @default.
• W2013784259 hasConcept C168563851 @default.
• W2013784259 hasConcept C197934379 @default.
• W2013784259 hasConcept C2777137803 @default.
• W2013784259 hasConcept C2777397205 @default.
• W2013784259 hasConcept C2777917749 @default.
• W2013784259 hasConcept C2778451229 @default.
• W2013784259 hasConcept C2778866283 @default.
• W2013784259 hasConcept C71924100 @default.
• W2013784259 hasConcept C90924648 @default.
• W2013784259 hasConceptScore W2013784259C126322002 @default.
• W2013784259 hasConceptScore W2013784259C141071460 @default.
• W2013784259 hasConceptScore W2013784259C168563851 @default.
• W2013784259 hasConceptScore W2013784259C197934379 @default.
• W2013784259 hasConceptScore W2013784259C2777137803 @default.
• W2013784259 hasConceptScore W2013784259C2777397205 @default.
• W2013784259 hasConceptScore W2013784259C2777917749 @default.
• W2013784259 hasConceptScore W2013784259C2778451229 @default.
• W2013784259 hasConceptScore W2013784259C2778866283 @default.
• W2013784259 hasConceptScore W2013784259C71924100 @default.
• W2013784259 hasConceptScore W2013784259C90924648 @default.
• W2013784259 hasIssue "20" @default.
• W2013784259 hasLocation W20137842591 @default.
• W2013784259 hasLocation W20137842592 @default.
• W2013784259 hasLocation W20137842593 @default.
• W2013784259 hasLocation W20137842594 @default.
• W2013784259 hasOpenAccess W2013784259 @default.
• W2013784259 hasPrimaryLocation W20137842591 @default.
• W2013784259 hasRelatedWork W1885119358 @default.
• W2013784259 hasRelatedWork W1967332781 @default.
• W2013784259 hasRelatedWork W1989187851 @default.

• next